Bevacizumab plus IFN-alpha-2a in First-line Treatment of Patients With Advanced or Metastatic Renal Cell Carcinoma: A Prospective German Non-interventional Study

Article Information

vol. 39 no. 2 875-882

DOI

PMID

Published By

Print ISSN

0250-7005

Online ISSN

1791-7530

History

¹University Hospital Freiburg (Albert-Ludwigs-University) Urology, Freiburg, Germany
²PIOH Study and Management GbR, Frechen, Germany
³Specialist for Internal Medicine Hematology and Oncology, Neustadt, Germany
⁴Roche Pharma AG Germany, Grenzach-Wyhlen, Germany

Correspondence to: Prof. Dr. Wolfgang Schulze-Seemann, University Hospital Freiburg, Clinic for Urology, Hugstetter Street 55, 79106 Freiburg. Tel: +49 76127028920, Fax: +49 76127028780, e-mail: wolfgang.schultze-seemann{at}uniklinik-freiburg.de; sekretariat.schultze-seemann{at}uniklinik-freiburg.de